已发表论文

二甲双胍治疗对癌症和糖尿病患者放疗疗效的影响:一个系统评价和荟萃分析

 

Authors Rao M, Gao C, Guo M, Law BYK, Xu Y

Received 17 May 2018

Accepted for publication 30 August 2018

Published 24 October 2018 Volume 2018:10 Pages 4881—4890

DOI https://doi.org/10.2147/CMAR.S174535

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Professor Nakshatri

Purpose: Metformin is a key pharmaceutical for patients with diabetes mellitus (DM). Metformin also can enhance tumor radiosensitivity in vitro and in vivo. Some retrospective cohort studies have indicated that metformin can improve the efficacy of radiotherapy in patients with cancer and DM. The aim of this systematic review was to evaluate the radiotherapy efficacy of metformin in patients with cancer and DM.
Methods: Multiple databases were queried for studies that address the efficacy of metformin in radiotherapy of patients with cancer and DM. Studies were included that involved comparisons of the short-term tumor responses and long-term survival outcomes of these patients who were managed with or without metformin as well as of nondiabetic patients without metformin. The OR and HR with accompanying 95% CI were assessed in a random effects model. The main endpoints were 2-year and 5-year overall survival (2y-OS and 5y-OS, respectively).
Results: The database search yielded 17 cohort studies that met the inclusion criteria. The results indicated that the tumor response was higher in patients who also were treated with metformin than in those who were not (OR, 0.48; 95% CI, 0.22–1.07; =0.07) and nondiabetic (OR, 0.27; 95% CI, 0.07–0.98; =0.05). Moreover, patients who received metformin had survival benefits compared with patients not treated with metformin (2y-OS: OR, 0.48; 95% CI, 0.29–0.80; P=0.005; 5y-OS: OR, 0.38; 95% CI, 0.25–0.56; <0.00001). The metformin-related HRs of OS values were not significantly different.
Conclusion: Metformin appears to improve the tumor response to radiotherapy in patients with cancer and DM and partly yield survival benefits. Despite the apparent advantages provided by metformin treatment on 2y-OS and 5y-OS, these retrospective data are at risk of bias and should be interpreted with caution.
Keywords: metformin, cancer, diabetes mellitus, radiotherapy, survival




Figure 1 Flow diagram showing study selection.